Evidence map›Paper›PMID 40773189›Full record

ArticleJAMA otolaryngology-- head & neck surgery2025

Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.

Paolo Farneti, Sol Marcos-Salazar, Claudia Crocione, Holly Boyer, Roberto Puxeddu, Alan B Whitehouse, Jay F Piccirillo

Abstract readConsensus Statement
In one paragraph

Article in JAMA otolaryngology-- head & neck surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paolo FarnetiDepartment of Otorhinolaryngology, Ospedale Bellaria, Dip. Chirurgie Specialistiche, AUSL Bologna, Bologna, Italy.
Sol Marcos-SalazarDepartment of Otorhinolaryngology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Claudia CrocioneHHT Italia-Associazione di Promozione Sociale, Rome, Italy.
Holly BoyerDepartment of Otolaryngology, University of Minnesota, Minneapolis.
Roberto PuxedduUnit of Otorhinolaryngology, Department of Surgery, Azienda Ospedaliero-Universitaria di Cagliari, University of Cagliari, Cagliari, Italy.
Alan B WhitehouseOtolaryngology HHT Center of Excellence Medical College of Georgia, Augusta.
Jay F PiccirilloDepartment of Otolaryngology-Head and Neck Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Sclerotherapy involves injecting a sclerosing agent into the nasal, oral mucosa, and cutaneous telangiectasias to reduce bleeding, demonstrating both safety and efficacy as a treatment. Despite its proven benefits, few physicians currently offer this therapy to patients with hereditary hemorrhagic telangiectasia (HHT). Objective: To promote the safe use of sclerotherapy among patients with HHT. Design, Setting, and Participants: In this survey study, a modified Delphi protocol was used to achieve consensus on sclerotherapy among a panel of 6 experts. The Delphi consensus took place through online meetings and surveys sent via Google Forms. Six experts from Italy, Spain, and the US, each with more than 10 years of experience in the use of sclerotherapy for HHT-associated epistaxis and cutaneous telangiectasias, participated in the Delphi protocol. Main Outcomes and Measures: This approach included 3 rounds of ratings interspersed with an in-person discussion led by an experienced moderator to resolve disagreements. Experts in using specific sclerotherapy agents (sodium tetradecyl sulfate and polidocanol), both in liquid or foam form, participated in surveys. Consensus was defined as agreement among 4 of 6 panelists. After discussions and clarifications, 3 survey rounds were conducted, resulting in consensus on all 30 statements across 7 domains. Results: The consensus among 6 experts indicates that stable patients with HHT are eligible for sclerotherapy, with individualized precautions based on medical history and comorbidities. In-office sclerotherapy provides several advantages, including quick access, high patient satisfaction, and the elimination of general anesthesia risks, despite the occasional occurrence of vasovagal events and moderate bleeding. According to the 2015 European Society of Cardiology guideline, antibiotic prophylaxis is recommended for patient preparation, while fasting is generally not necessary. Specific precautions for preventing complications such as septal perforation and amaurosis were identified. Adverse effects are usually mild to moderate, with severe bleeding being rare. Practitioners should have expertise in endoscopy or rhinoscopy, thorough pathology knowledge, and training from experienced professionals. Conclusions and Relevance: In this survey study, the consensus of 6 experts produced 30 statements guiding patient care and safe procedure implementation. While not formal treatment guidelines, these statements offer valuable insights for clinicians seeking to adopt or align with expert recommendations. Further validation and research are encouraged to ensure these consensus statements improve patient care and outcomes.

Indexed as

EpistaxisSclerosing SolutionsSclerotherapyTelangiectasia, Hereditary HemorrhagicDelphi TechniqueHumansPolidocanolSodium Tetradecyl SulfatePolidocanolSclerosing SolutionsSodium Tetradecyl Sulfate

Identifiers

PMID40773189
PMCPMC12332757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.